Find Reports

Select Report Type

Reimbursement Review

Displaying 526 - 550 of 1426

Please scroll or swipe to the right to view the full content.

Title	Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
Buprenorphine hydrochloride	Probuphine	buprenorphine hydrochloride	SR0550_Probuphine_Aug_24_18.pdf SR0550_Probuphine_CL_Report.pdf SR0550_Probuphine_PE_Report.pdf	Opioid drug dependence, treatment	Reimburse with clinical criteria and/or conditions	Complete	Dec 21, 2017	Aug 22, 2018	SR0550-000
Levodopa / carbidopa (Drug Pla...	Duodopa	Levodopa / carbidopa (Drug Plan Submission)	SR0557_Duodopa_Aug_24-18.pdf SR0557_DuodopaFWG_CL_Report.pdf SR0557_DuodopaFWG_PE_Report.pdf SR0557_Duodopa_PI_Submissions.pdf si0001-duodopa-drug-implementation-advice.pdf	Parkinson's disease	Reimburse with clinical criteria and/or conditions	Complete	Feb 8, 2018	Aug 22, 2018	SR0557-000
ixekizumab	Taltz	ixekizumab	SR0558_Taltz_PsA_Aug_23_18.pdf SR0558_TaltzPsA_CL_Report.pdf SR0558_TaltzPsA_PE_Report.pdf SR0558_TaltzPsA_PI_Submissions.pdf	Arthritis, psoriatic	Reimburse with clinical criteria and/or conditions	Complete	Feb 20, 2018	Aug 21, 2018	SR0558-000
benralizumab	Fasenra	benralizumab	SR0561_Fasenra_Aug_23_18.pdf SR0561_Fasenra_CL_Report.pdf SR0561_Fasenra_PE_Report.pdf SR0561_Fasenra_PI_Submissions.pdf	Asthma, severe eosinophilic	Reimburse with clinical criteria and/or conditions	Complete	Feb 23, 2018	Aug 21, 2018	SR0561-000
Darunavir/cobicistat/emtricita...	Symtuza	Darunavir/cobicistat/emtricitabine/tenofovir alafenamide	SR0552_cdr_complete_Symtuza_July_27_18.pdf SR0552_Symtuza_Combined_Report.pdf SR0552_Symtuza_PI_Submissions.pdf	HIV-1 infection	Reimburse with clinical criteria and/or conditions	Complete	Dec 22, 2017	Jul 25, 2018	SR0552-000
Alecensaro for Non-Small Cell ...	Alecensaro	Alectinib	pcodr_provfund_alectinib_alecensaro_nsclc_1ln.pdf pcodr_alectinib_alecensaro_nsclc_1stln_fn_rec.pdf pcodr_alectinib_alecensaro_nsclc_1stln_fn_cgr.pdf pcodr_alectinib_alecensaro_nsclc_1stln_fn_egr.pdf pcodr_alectinib_alecensaro_nsclc_1stln_in_rec.pdf pcodr_alectinib_alecensaro_nsclc_1stln_pagfdk.pdf pcodr_alectinib_alecensaro_nsclc_1stln_fdk_hlr.pdf pcodr_alectinib_alecensaro_nsclc_1stln_clnfdk.pdf pcodr_alectinib_alecensaro_nsclc_1stln_coi_pt.pdf pcodr_alectinib_alecensaro_nsclc_1stln_coi_cln.pdf	Locally advanced or metastatic ALK+ NSCLC (first line)	Reimburse with clinical criteria and/or conditions	Complete	Jan 15, 2018	Jul 25, 2018	PC0125-000
Lonsurf for Metastatic Colorec...	Lonsurf	Trifluridine and Tipiracil	pcodr_provfund_trifluridine_tipiracil_lonsurf_mcrc.pdf pcodr_trifluridine_tipiracil_lonsurf_mcrc_fn_rec.pdf pcodr_trifluridine_tipiracil_lonsurf_mcrc_fn_cgr.pdf pcodr_trifluridine_tipiracil_lonsurf_mcrc_fn_egr.pdf pcodr_trifluridine-tipiracil_Lonsurf_mCRC_in_rec.pdf pcodr_trifluridine_tipiracil_lonsurf_mcrc_pagfdk.pdf pcodr_trifluridine_tipiracil_lonsurf_mcrc_fdk_taiho.pdf pcodr_trifluridine_tipiracil_lonsurf_mcrc_ptfdk.pdf pcodr_trifluridine_tipiracil_lonsurf_mcrc_clnfdk.pdf pcodr_trifluridine_tipiracil_lonsurf_mcrc_coi_pt.pdf pcodr_trifluridine_tipiracil_lonsurf_mcrc_coi_cln.pdf	Metastatic Colorectal Cancer	Do not reimburse	Complete	Nov 6, 2017	Jul 6, 2018	PC0122-000
Besponsa for Acute Lymphoblast...	Besponsa	Inotuzumab Ozogamicin	pcodr_provfund_inotuzumab-ozogamicin_besponsa_all.pdf pcodr_inotuzumab_ozogamicin_besponsa_all_fn_rec.pdf pcodr_inotuzumab_ozogamicin_besponsa_all_fn_cgr.pdf pcodr_inotuzumab_ozogamicin_besponsa_all_fn_egr.pdf pcodr_inotuzumab_besponsa_ALL_in_rec.pdf pcodr_inotuzumab_ozogamicin_besponsa_all_pagfdk.pdf pcodr_inotuzumab_ozogamicin_besponsa_all_fdk_pfizer.pdf pcodr_inotuzumab_ozogamicin_besponsa_all_clnfdk.pdf pcodr_inotuzumab_ozogamicin_besponsa_all_coi_pt.pdf pcodr_inotuzumab_ozogamicin_besponsa_all_coi_cln.pdf	Acute Lymphoblastic Leukemia (ALL)	Reimburse with clinical criteria and/or conditions	Complete	Nov 13, 2017	Jul 6, 2018	PC0121-000
dupilumab	Dupixent	dupilumab	SR0533_cdr_complete_Dupixent_July_9_2018.pdf SR0533_Dupixent_CL_Report.pdf SR0533_Dupixent_PE_Report.pdf SR0533_Duxipent_Patient_Submsissions.pdf	atopic dermatitis	Do not reimburse	Complete	Oct 27, 2017	Jun 27, 2018	SR0533-000
netupitant / palonosetron	Akynzeo	netupitant / palonosetron	SR0548_cdr_complete_Akynzeo_June_22_18.pdf SR0548_Akynzeo_CL_Report.pdf SR0548_Akynzeo_PE_Report.pdf	Nausea and vomiting (chemotherapy induced) prevention	Reimburse with clinical criteria and/or conditions	Complete	Dec 8, 2017	Jun 20, 2018	SR0548-000
Tecentriq for Non-Small Cell L...	Tecentriq	Atezolizumab	pcodr_profund_10115_atezolizumab_tecentriq_nsclc.pdf pcodr_atezolizumab_tecentriq_nsclc_fn_rec.pdf pcodr_atezolizumab_tecentriq_nsclc_fn_cgr.pdf pcodr_atezolizumab_tecentriq_nsclc_fn_egr.pdf pcodr_atezolizumab_tecentriq_nsclc_in_rec.pdf pcodr_atezolizumab_tecentriq_nsclc_pagfdk.pdf pcodr_atezolizumab_tecentriq_nsclc_fdk_hlroche.pdf pcodr_atezolizumab_tecentriq_nsclc_clnfdk.pdf pcodr_atezolizumab_tecentriq_nsclc_coi_pt.pdf pcodr_atezolizumab_tecentriq_nsclc_coi_cln.pdf	Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)	Reimburse with clinical criteria and/or conditions	Complete	Dec 15, 2017	Jun 20, 2018	PC0115-000
Dolutegravir / rilpivirine	Juluca	Dolutegravir rilpivirine	SR0551_cdr_complete_Juluca_June_22_18.pdf SR0551_Juluca_CL_Report.pdf SR0551_Juluca_PE_Report.pdf SR0551_Juluca_PI_Submissions.pdf	HIV infection	Reimburse with clinical criteria and/or conditions	Complete	Dec 21, 2017	Jun 20, 2018	SR0551-000
letermovir	Prevymis	letermovir	SR0545_cdr_complete_Prevymis_June_22_2018.pdf SR0545_Prevymis_CL_Report.pdf SR0545_Prevymis_PE_Report.pdf SR0545_Prevymis_PI_Submissions.pdf	Cytomegalovirus infection, prophylaxis	Reimburse with clinical criteria and/or conditions	Complete	Dec 7, 2017	Jun 20, 2018	SR0545-000
brodalumab	Siliq	brodalumab	TS0001-PsO-Updated-Streamlined-Rec.pdf SR0547_cdr_complete_Siliq_June_22_18.pdf SR0547_Siliq_CL_Report.pdf SR0547_Siliq_PE_Report.pdf SR0547_Brodalumab_PI_Submissions.pdf	Psoriasis, moderate to severe plaque	Reimburse with clinical criteria and/or conditions	Complete	Dec 14, 2017	Jun 20, 2018	SR0547-000
Opdivo for classical Hodgkin L...	Opdivo	Nivolumab	pcodr_profund_nivolumab_opdivo_chl_fail_asct.pdf pcodr_nivolumab_opdivo_cHL_fn_rec.pdf pcodr_nivolumab_opdivo_cHL_fn_egr.pdf pcodr_nivolumab_opdivo_cHL_fn_cgr.pdf pcodr_nivolumab_opdivo_chl_in_rec.pdf pcodr_nivolumab_opdivo_cHL_pagfdk.pdf pcodr_nivolumab_opdivo_cHL_ptfdk.pdf pcodr_nivolumab_opdivo_cHL_clnfdk.pdf pcodr_nivolumab_opdivo_cHL_fdk_bms.pdf pcodr_nivolumab_opdivo_cHL_coi_pt.pdf pcodr_nivolumab_opdivo_cHL_coi_cln.pdf	classical Hodgkin Lymphoma (cHL) after failure of ASCT	Reimburse with clinical criteria and/or conditions	Complete	Sep 29, 2017	May 3, 2018	PC0120-000
ocrelizumab	Ocrevus	ocrelizumab	SR0542_cdr_complete_Ocrevus_PPMS_Apr_30_18_e.pdf SR0542_Ocrevus_PPMS_CL_Report.pdf SR0542_Ocrevus_PPMS_PE_Report.pdf SR0542_Ocrevus_PPMS_PI_Submissions.pdf	Primary progressive multiple sclerosis	Reimburse with clinical criteria and/or conditions	Complete	Oct 26, 2017	Apr 26, 2018	SR0542-000
nitisinone	MDK-Nitisinone	nitisinone	SR0538_cdr_complete_MDK_Nitisinone_Apr_27_18_e.pdf SR0538_MDK_Nitisinone_CL_Report.pdf SR0538_MDK_Nitisinone_PE_Report.pdf SR0538_MDK_Nitisinone_PI_Submissions.pdf	Hereditary tyrosinemia type 1	Reimburse with clinical criteria and/or conditions	Complete	Sep 29, 2017	Apr 25, 2018	SR0538-000
latanoprost	Monoprost	latanoprost	SR0541_cdr_complete_Monoprost_apr-26-18_e.pdf SR0541_Monoprost_CL_Report.pdf SR0541_Monoprost_PE_Report.pdf	glaucoma and ocular hypertension	Reimburse with clinical criteria and/or conditions	Complete	Oct 25, 2017	Apr 24, 2018	SR0541-000
Lartruvo for Advanced Soft Tis...	Lartruvo	Olaratumab	pcodr_profund_olaratumab_lartruvo_sts.pdf pcodr_olaratumab_lartruvo_sts_fn_rec.pdf pcodr_olaratumab_lartruvo_sts_fn_cgr.pdf pcodr_olaratumab_lartruvo_sts_fn_egr.pdf pcodr_olaratumab_lartruvo_sts_in_rec.pdf pcodr_olaratumab_lartruvo_sts_pagfdk.pdf pcodr_olaratumab_lartruvo_sts_fdk_elc.pdf pcodr_olaratumab_lartruvo_sts_clnfdk.pdf pcodr_olaratumab_lartruvo_sts_coi_pt.pdf pcodr_olaratumab_lartruvo_sts_coi_cln.pdf	Advanced Soft Tissue Sarcoma	Reimburse with clinical criteria and/or conditions	Complete	Oct 26, 2017	Apr 18, 2018	PC0111-000
Stivarga for Unresectable Hepa...	Stivarga	Regorafenib	pcodr_provfund_10119_regorafenib_stivarga_unresectable_hcc.pdf pcodr_regorafenib_stivarga_hcc_fn_rec.pdf pcodr_regorafenib_stivarga_hcc_fn_cgr.pdf pcodr_regorafenib_stivarga_hcc_fn_egr.pdf pcodr_regorafenib_stivarga_hcc_in_rec.pdf pcodr_regorafenib_stivarga_hcc_pagfdk.pdf pcodr_regorafenib_stivarga_hcc_fdk_bayer.pdf pcodr_regorafenib_stivarga_hcc_ptfdk.pdf pcodr_regorafenib_stivarga_hcc_clnfdk.pdf pcodr_regorafenib_stivarga_hcc_coi_pt.pdf pcodr_regorafenib_stivarga_hcc_coi_cln.pdf	Unresectable Hepatocellular Carcinoma (HCC)	Reimburse with clinical criteria and/or conditions	Complete	Oct 12, 2017	Apr 18, 2018	PC0119-000
Kisqali for Metastatic Breast ...	Kisqali	Ribociclib	pcodr_provfund_10112_ribocliclib_kisqali_mbc.pdf pcodr_ribociclib_kisqali_mbc_fn_rec.pdf pcodr_ribociclib_kisqali_mbc_fn_cgr.pdf pcodr_ribociclib_kisqali_mbc_fn_egr.pdf pcodr_ribociclib_kisqali_mbc_in_rec.pdf pcodr_ribociclib_kisqali_mbc_pagfdk.pdf pcodr_ribociclib_kisqali_mbc_fdk_novartis.pdf pcodr_ribociclib_kisqali_mbc_ptfdk.pdf pcodr_ribociclib_kisqali_mbc_clnfdk.pdf pcodr_ribociclib_kisqali_mbc_coi_pt.pdf pcodr_ribociclib_kisqali_mbc_coi_cln.pdf	Advanced or Metastatic Breast Cancer	Reimburse with clinical criteria and/or conditions	Complete	Oct 17, 2017	Apr 18, 2018	PC0112-000
Vectibix for Left Sided Metast...	Vectibix	Panitumumab	pcodr_profund_panitumumab_vectibix_ls_mcrc.pdf pcodr_panitumumab_vectibix_ls_mcrc_fn_rec.pdf pcodr_panitumumab_vectibix_ls_mcrc_fn_cgr.pdf pcodr_panitumumab_vectibix_ls_mcrc_fn_egr .pdf pcodr_panitumumab_vectibix_ls_mcrc_in_rec.pdf pcodr_panitumumab_vectibix_ls_mcrc_pagfdk.pdf pcodr_panitumumab_vectibix_ls_mcrc_fdk_amgen.pdf pcodr_panitumumab_vectibix_ls_mcrc_ptfdk.pdf pcodr_panitumumab_vectibix_ls_mcrc_clnfdk.pdf pcodr_panitumumab_vectibix_ls_mcrc_coi_pt.pdf pcodr_panitumumab_vectibix_ls_mcrc_coi_cln.pdf	Left Sided Metastatic Colorectal Cancer (mCRC)	Do not reimburse	Complete	Sep 8, 2017	Mar 29, 2018	PC0118-000
Alecensaro for Locally Advance...	Alecensaro	Alectinib	AlectinibAlecensaro_NSCLCsecondline10114ProvFunding.pdf pcodr_alectinib_alecensaro_nsclc_2ln_fn_rec.pdf pcodr_alectinib_alecensaro_nsclc_2ln_fn_cgr .pdf pcodr_alectinib_alecensaro_nsclc_2ln_fn_egr.pdf pcodr_alectinib_alecensaro_nsclc_2ln_in_rec.pdf pcodr_alectinib_alecensaro_nsclc_2ln_pagfdk.pdf pcodr_alectinib_alecensaro_nsclc_2ln_fdk_roche.pdf pcodr_alectinib_alecensaro_nsclc_2ln_coi_pt.pdf pcodr_alectinib_alecensaro_nsclc_2ln_coi_cln.pdf	Anaplastic Lymphoma Kinase-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Reimburse with clinical criteria and/or conditions	Complete	Aug 18, 2017	Mar 29, 2018	PC0114-000
tocilizumab	Actemra	tocilizumab	SR0534_Actemra_GCA_complete_Mar-27-18.pdf SR0534_ActemraGCA_CL_Report.pdf SR0534_Actemra_GCA_PE_Report.pdf SR0534_Actemra_GCA_PI_Submissions.pdf	Giant cell arteritis (GCA)	Reimburse with clinical criteria and/or conditions	Complete	Sep 25, 2017	Mar 27, 2018	SR0534-000
tenofovir alafenamide	Vemlidy	tenofovir alafenamide	SR0537_Vemlidy_complete_Mar-28-18.pdf SR0537_Vemlidy_CL_Report.pdf SR0537_Vemlidy_PE_Report.pdf SR0537_Vemlidy_PI_Submissions.pdf	Hepatitis B, chronic	Reimburse with clinical criteria and/or conditions	Complete	Sep 28, 2017	Mar 26, 2018	SR0537-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 526 - 550 of 602

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Sub Line	Status	Project Number
Botulinum Toxin for Temporomandibular Disorders: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines	RC1245 Botox for TMD Final.pdf	Mar 2, 2020	Summary with Critical Appraisal	Completed	RC1245-000
Manual Therapy for Persistent, Non-Cancer Back and Neck Pain: A Review of Clinical Effectiveness	RC1231 Manual Therapy Neck Back Final.pdf	Mar 2, 2020	Summary with Critical Appraisal	Completed	RC1231-000
Non-pharmacological and Pharmacological Intervention for Smoking Cessation Programs in Youth: A Review of Clinical Effectiveness and Guidelines	RC1235 Smoking Cessation Youth Final.pdf	Mar 2, 2020	Summary with Critical Appraisal	Completed	RC1235-000
Orthotic Bracing or Splinting of Upper Extremities in Patients with Chronic, Non-Cancer Pain: A Review of Clinical Effectiveness	RC1252 Splinting for Upper Extremity Pain Final.pdf	Mar 2, 2020	Summary with Critical Appraisal	Completed	RC1252-000
Magnetic Localization System for Sentinel Lymph Node Biopsy: A Review of the Diagnostic Accuracy, Cost-Effectiveness, and Guidelines	RC1249 Magtrace Final.pdf	Mar 2, 2020	Summary with Critical Appraisal	Completed	RC1249-000
Prenatal and Postnatal Home Visiting Programs for Parents, Newborns, and Babies: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines	RC1243 Home Visit Programs Final.pdf	Feb 26, 2020	Summary with Critical Appraisal	Completed	RC1243-000
Lurasidone Hydrochloride for Bipolar Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines	RC1244 Lurasidone for BD Final.pdf	Feb 26, 2020	Summary with Critical Appraisal	Completed	RC1244-000
Pilocarpine for Xerostomia and Xerophthalmia in Sjögren’s Syndrome: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines	RC1227- Pilocarpine for SIX Final.pdf	Feb 26, 2020	Summary with Critical Appraisal	Completed	RC1227-000
Palivizumab For Infection Prevention in Inuit Infants: A Review of the Clinical Effectiveness and Cost-Effectiveness	RC1217 Palivizumab Prophylaxis Final.pdf	Feb 24, 2020	Summary with Critical Appraisal	Completed	RC1217-000
Ondansetron and Oral Rehydration Therapy in Pediatric Patients with Dehydration: Clinical Effectiveness	RC1242 ondansetron Final.pdf	Feb 24, 2020	Summary with Critical Appraisal	Completed	RC1242-000
Prostaglandin Analogues for Ophthalmic Use: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines	RC1248 Pros Analogues Final.pdf	Feb 24, 2020	Summary with Critical Appraisal	Completed	RC1248-000
Quetiapine for Major Depressive Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines	RC1233 Quetiapine for MDD Final.pdf	Feb 24, 2020	Summary with Critical Appraisal	Completed	RC1233-000
Combination Use of Ivabradine with Sacubitril/Valsartan: A Review of Clinical Effectiveness and Guidelines	RC1247 Ivabradine Sacubitril Valsartan Final.pdf	Feb 24, 2020	Summary with Critical Appraisal	Completed	RC1247-000
Intraosseous Contrast Media Injection for Computed Tomography Scan or Magnetic Resonance Imaging: A Review of Clinical Effectiveness and Guidelines	RC1234 Intraosseous Devices Final.pdf	Feb 24, 2020	Summary with Critical Appraisal	Completed	RC1234-000
Major Depressive Disorder – Focused Critical Appraisal of a Network Meta-Analysis	he0022-major-depressive-disorder-critical-appraisal.pdf	Feb 18, 2020	Technology Review	Completed	HE0022-000
Clozapine Initiation for Schizophrenia: A Review of Clinical Effectiveness and Guidelines	RC1229 Clozapine Initiation Final.pdf	Feb 18, 2020	Summary with Critical Appraisal	Completed	RC1229-000
Pilocarpine for Radiotherapy-Induced Dry Mouth and Dry Eyes: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines	RC1226 Pilocarpine for RIX Final.pdf	Feb 18, 2020	Summary with Critical Appraisal	Completed	RC1226-000
Pharmacogenomic Testing in Depression: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines	RC1232 RxGx testing depression Final.pdf	Feb 18, 2020	Summary with Critical Appraisal	Completed	RC1232-000
Artificial Intelligence for Classification of Lung Nodules: A Review of Clinical Utility, Diagnostic Accuracy, Cost-Effectiveness, and Guidelines	RC1228 AI for Lung Nodules Final.pdf	Feb 18, 2020	Summary with Critical Appraisal	Completed	RC1228-000
Physical Activity for Chronic Osteoarthritic Knee Pain: A Review of Clinical Effectiveness	RC1230 Physical Activity for KOA Final.pdf	Feb 17, 2020	Summary with Critical Appraisal	Completed	RC1230-000
Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy: A Critical Appraisal of the MENTOR Study	ha0001-mentor-study-focused-crititcal-appraisal.pdf	Jan 23, 2020	Technology Review	Completed	HA0001-000
Utilization of Innovator Biologics and Biosimilars for Chronic Inflammatory Diseases in Canada: A Provincial Perspective		Jan 21, 2020			HO0007-HE0024
Internet-Based Cognitive Behavioural Therapy for Post-Traumatic Stress Disorder		Jan 20, 2020	Optimal Use	Completed	OP0537-000
csDMARDS for Rheumatoid Arthritis	op0539-cs-dmards-for-ra-fca-correction.pdf	Jan 16, 2020	Technology Review	Completed	HE0029-000
Elevated Vacuum Suspension Systems for Adults with Amputation: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines	RC1224 EVSS Final.pdf	Jan 15, 2020	Summary with Critical Appraisal	Completed	RC1224-000

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 110 of 110

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 27 of 27

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 526 - 550 of 2138

Please scroll or swipe to the right to view the full content.

Title	Description	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
Hernia Support Garments for Parastomal Hernia Following Ostomy Procedure		Hernia Support Garments for Parastomal Hernia Following Ostomy Procedure	Jan 8, 2024	Health Technology Review	Rapid Review	Completed	RC1520-000
Artificial Intelligence Decision Support Tools for End-of-life Care Planning Conversations		Artificial Intelligence Decision Support Tools for End-of-life Care Planning Conversations	Dec 22, 2023	Horizon Scan	Health Technology Update	Completed	EN0053-000
ChatGPT in Radiology: Appropriate Imaging and Workflow Efficiencies		ChatGPT in Radiology: Appropriate Imaging and Workflow Efficiencies	Dec 21, 2023	Health Technology Review	CMII Service	Completed	CM0009-000
Early Intervention Programs for Adolescents and Young Adults With Eating Disorders		Main Report Supporting Information Project Protocol	Dec 18, 2023	Health Technology Review	Health Technology Assessment	Completed	HT0040-000 - OP0552-000
Aging in Place	Our Health Technology Expert Review Panel convened to develop objective, impartial, trusted pan-Canadian guidance to inform decisions about which evidence-informed, equitable, aging in place initiatives across jurisdictions can support aging in place in Canada.	Evidence Assessment Report Supporting Information Summary of Engagement Activities Guidance	Dec 13, 2023	Health Technology Review	Optimal Use	Active	OP0555-000
Emerging Drugs for Relapsed or Refractory Peripheral T-Cell Lymphoma		Emerging Drugs for Relapsed or Refractory Peripheral T-Cell Lymphoma	Dec 12, 2023	Horizon Scan	Emerging Health Technologies	Completed	EH0119-000
Pathology Implementation Advice Panel: Guidance for Reporting Diagnostic Classifications for Breast Cancer		Pathology Implementation Advice Panel: Guidance for Reporting Diagnostic Classi…	Dec 7, 2023	Health Technology Review	Technology Review	Completed	HC0070-000
HR+ HER2- Breast Cancer and Triple Negative Breast Cancer, with inclusion of HER2 Low Breast Cancer		Final Report	Dec 7, 2023	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0033-000
Technologies to Increase Freedom for People Living With Dementia		Technologies to Increase Freedom for People Living With Dementia	Dec 6, 2023	Horizon Scan	Emerging Health Technologies	Completed	EH0113-000
CADTH Pharmaceutical Reviews Update — Issue 42			Nov 30, 2023	Reimbursement Review	Pharmaceutical Review Update
zanubrutinib		Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Nov 29, 2023	Reimbursement Review		Complete	PC0310-000
An Analysis of Demographic and Utilization Patterns of Patients Accessing Emergency Departments in Canada		Emergency Department Overcrowding: Utilization Analysis Emergency Department Overcrowding: Utilization Analysis: Methods Document	Nov 28, 2023	Health Technology Review	Technology Review	Complete	HC0061-000
Emergency Department Overcrowding in Canada: An Update		CADTH Guidance: Emergency Department Overcrowding Contributing Factors and Intervention Effectiveness Supporting Information: Factors and Intervention Effectiveness Multistakeholder Dialogue Protocol: Contributing Factors and Intervention Effectiveness Evidence Preview: Factors and Intervention Effectiveness	Nov 24, 2023	Health Technology Review	Optimal Use	Completed	OP0553-000 - RE0044-000
clascoterone			Nov 17, 2023	Reimbursement Review		Withdrawn	SR0786-000
belzutifan		Recommendation and Reasons Clinical, Pharmacoeconomic, Ethics, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Nov 16, 2023	Reimbursement Review		Complete	PC0309-000
Vital Signs Monitoring Sticker		Vital Signs Monitoring Sticker	Nov 14, 2023	Horizon Scan	Health Technology Update	Completed	EN0048-000
dabrafenib trametinib			Nov 10, 2023	Reimbursement Review		Cancelled	PC0337-000
Biologics in Plaque Psoriasis		Streamlined Drug Class Review – Final Recommendation and Reasons Responses to Questions From the Drug Programs Updated CADTH Reimbursement Recommendations CADTH Review - Final Summary Report	Nov 9, 2023	Reimbursement Review	Streamlined Drug Class Review	Complete	TS0001-000
Case Carts in Surgical Settings		Case Carts in Surgical Settings	Nov 8, 2023	Health Technology Review	Rapid Review	Completed	RC1512-000
Routine Dental Polishing for Oral Health		Routine Dental Polishing for Oral Health	Nov 8, 2023	Health Technology Review	Rapid Review	Completed	RC1517-000
Intrathecal Drug Delivery Systems for Cancer Pain			Nov 6, 2023	Health Technology Review	Technology Review	Completed	HC0058-000
Buprenorphine Naloxone Film versus Tablets for Opioid Use Disorder	CADTH's Health Technology Review identifies and summarizes literature comparing the effectiveness and cost-effectiveness of sublingual buprenorphine-naloxone films versus tablets.	Buprenorphine Naloxone Film versus Tablets for Opioid Use Disorder	Nov 6, 2023	Health Technology Review	Rapid Review	Completed	RC1513-000
Intraocular Lenses for Cataract Surgery		Intraocular Lenses for Cataract Surgery	Nov 6, 2023	Health Technology Review	Rapid Review	Completed	RC1515-000
Anti–Vascular Endothelial Growth Factor Drugs for Age-Related Macular Degeneration		Anti–Vascular Endothelial Growth Factor Drugs for Age-Related Macular Degeneration	Nov 6, 2023	Health Technology Review	Rapid Review	Completed	RC1510-000
Supplemental Screening Modalities for People With Dense Breasts			Nov 1, 2023	Health Technology Review	Technology Review	Completed	HC0026-000

Provisional Funding Algorithm

Displaying 76 - 81 of 81